181 related articles for article (PubMed ID: 20835859)
1. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
2. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.
Weinstein D; Simon M; Yehezkel E; Laron Z; Werner H
Diabetes Metab Res Rev; 2009 Jan; 25(1):41-9. PubMed ID: 19145584
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
4. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Sciacca L; Cassarino MF; Genua M; Pandini G; Le Moli R; Squatrito S; Vigneri R
Diabetologia; 2010 Aug; 53(8):1743-53. PubMed ID: 20424816
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir.
Varewijck AJ; Goudzwaard JA; Brugts MP; Lamberts SW; Hofland LJ; Janssen JA
Growth Horm IGF Res; 2010 Dec; 20(6):427-31. PubMed ID: 21055982
[TBL] [Abstract][Full Text] [Related]
6. Proliferative and signaling activities of insulin analogues in endometrial cancer cells.
Aizen D; Sarfstein R; Bruchim I; Weinstein D; Laron Z; Werner H
Mol Cell Endocrinol; 2015 May; 406():27-39. PubMed ID: 25697343
[TBL] [Abstract][Full Text] [Related]
7. Insulin and its analogs: actions via insulin and IGF receptors.
Vigneri R; Squatrito S; Sciacca L
Acta Diabetol; 2010 Dec; 47(4):271-8. PubMed ID: 20730455
[TBL] [Abstract][Full Text] [Related]
8. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.
Werner U; Korn M; Schmidt R; Wendrich TM; Tennagels N
Arch Physiol Biochem; 2014 Oct; 120(4):158-65. PubMed ID: 25144413
[TBL] [Abstract][Full Text] [Related]
11. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
12. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
13. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
[TBL] [Abstract][Full Text] [Related]
14. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Kurtzhals P; Schäffer L; Sørensen A; Kristensen C; Jonassen I; Schmid C; Trüb T
Diabetes; 2000 Jun; 49(6):999-1005. PubMed ID: 10866053
[TBL] [Abstract][Full Text] [Related]
15. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
16. Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts.
Warnken M; Reitzenstein U; Sommer A; Fuhrmann M; Mayer P; Enzmann H; Juergens UR; Racké K
Naunyn Schmiedebergs Arch Pharmacol; 2010 Dec; 382(5-6):511-24. PubMed ID: 20924562
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.
Wada T; Azegami M; Sugiyama M; Tsuneki H; Sasaoka T
Diabetes Res Clin Pract; 2008 Sep; 81(3):269-77. PubMed ID: 18585815
[TBL] [Abstract][Full Text] [Related]
19. Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice.
Yoon J; Subramanian S; Ding Y; Wang S; Goodspeed L; Sullivan B; Kim J; O'Brien KD; Chait A
Diabetologia; 2011 May; 54(5):1252-60. PubMed ID: 21327868
[TBL] [Abstract][Full Text] [Related]
20. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
